AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Personalized Medicine Market Analysis (2016 to 2026) - Total Market Value is Expected to Reach $3.92 Trillion by 2026 - ResearchAndMarkets.com

February 5, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Feb 5, 2020--

The “Global Personalized Medicine Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026 growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and Higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Key Questions Answered in this Report:

Based on the End User, the hospital’s segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals.

As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

5.1 Introduction

5.2 Diagnostics

5.3 Personalized Medical Care

5.4 Personalized Nutrition & Wellness

5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology

6.1 Introduction

6.2 Metabolomics

6.3 Pharmacodynamics

6.4 Pharmacogenetics

6.5 Pharmacogenomics

6.6 Pharmacokinetics

6.7 Pharmacoproteomics

6.8 Point-of-Care Testing

6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area

7.1 Introduction

7.2 Autoimmune Diseases

7.3 Blood Transfusion Safety

7.4 Cancer Management

7.5 Cardiovascular Diseases (CVD)

7.6 Central Nervous System (CNS) Disorders

7.7 Coagulation Therapy

7.8 Diabetes

7.9 Infectious Diseases

7.10 Antiviral

7.11 Neurology

7.12 Psychiatry

7.13 Oncology

7.14 Immunology

7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel

8.1 Introduction

8.2 Dietary Care Centers

8.3 Hospital’s Pharmacies

8.4 Retail Pharmacies

8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application

9.1 Introduction

9.2 Biomarker Identification

9.3 Clinical Research Applications

9.4 Companion Diagnostics

9.5 Health Informatics

10 Global Personalized Medicine Market, By End-User

10.1 Introduction

10.2 Academic Institutes

10.3 Bio and Health Informatics Companies

10.4 Clinical Care and Research Laboratories

10.5 Contract Research Organizations

10.6 Hospitals

10.7 Molecular Diagnostic Laboratories and Testing Facilities

10.8 Research Laboratories

10.9 Service Providers

10.10 Partner

10.11 Venture Capitalists

10.12 Other End Users

11 Global Personalized Medicine Market, By Geography

11.1 North America

11.2 Europe

11.3 Asia Pacific

11.4 South America

11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape

13.1 Abbott Laboratories

13.2 Affymetrix Incorporated

13.3 Agendia N.V

13.4 Agilent Technologies, Inc

13.5 Amgen, Inc

13.6 Asuragen Incorporated

13.7 Bayer Healthcare Pharmaceuticals, Llc

13.8 Celera Diagnostics LLC

13.9 Celgene Corporation

13.10 Roche Diagnostics Corporation

13.11 Precision Biologics Incorporated

13.12 Siemens Healthcare Diagnostics, Inc

13.13 Sigma-Aldrich Corporation

13.14 Johnson & Johnson

13.15 Novartis AG

13.16 Decode Genetics Inc.

13.17 Exact Science Corporation

13.18 Exagen Diagnostics Inc.

13.19 GE Healthcare

13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/n597b9

View source version on businesswire.com:https://www.businesswire.com/news/home/20200205005647/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 02/05/2020 12:19 PM/DISC: 02/05/2020 12:19 PM

http://www.businesswire.com/news/home/20200205005647/en